Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound

Market Focus06-15

On June 15, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.7/share, with turnover of HKD 363 million. The stock rebounded after consecutive sessions of decline, driven by dual catalysts of a new product approval and academic conference data.

The company recently received approval for its first domestic PCSK9 inhibitor injection, making it the tenth commercialized product in its portfolio and further strengthening its cardiovascular-metabolic pipeline. Additionally, mazdutide data presented at the 86th ADA Scientific Sessions — including three oral presentations covering severe obesity, type 2 diabetes with obesity, and adolescent obesity populations — provided further positive momentum.

The stock had previously pulled back from its May 29 peak gain of over 11% following the announcement of a USD 10.5 billion global strategic collaboration with Pfizer, as markets questioned regulatory approval certainty. Today's rebound was supported by broader biotech sector strength, with 3SBio rising 4.65% and Akeso gaining 1.14%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104771647?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 11:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104771647","market":"us","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound","media":"Market Focus","content":"<p><p>On June 15, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.7/share, with turnover of HKD 363 million. The stock rebounded after consecutive sessions of decline, driven by dual catalysts of a new product approval and academic conference data.</p><p>The company recently received approval for its first domestic PCSK9 inhibitor injection, making it the tenth commercialized product in its portfolio and further strengthening its cardiovascular-metabolic pipeline. Additionally, mazdutide data presented at the 86th ADA Scientific Sessions — including three oral presentations covering severe obesity, type 2 diabetes with obesity, and adolescent obesity populations — provided further positive momentum.</p><p>The stock had previously pulled back from its May 29 peak gain of over 11% following the announcement of a USD 10.5 billion global strategic collaboration with Pfizer, as markets questioned regulatory approval certainty. Today's rebound was supported by broader biotech sector strength, with 3SBio rising 4.65% and Akeso gaining 1.14%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-15 11:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 15, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.7/share, with turnover of HKD 363 million. The stock rebounded after consecutive sessions of decline, driven by dual catalysts of a new product approval and academic conference data.</p><p>The company recently received approval for its first domestic PCSK9 inhibitor injection, making it the tenth commercialized product in its portfolio and further strengthening its cardiovascular-metabolic pipeline. Additionally, mazdutide data presented at the 86th ADA Scientific Sessions — including three oral presentations covering severe obesity, type 2 diabetes with obesity, and adolescent obesity populations — provided further positive momentum.</p><p>The stock had previously pulled back from its May 29 peak gain of over 11% following the announcement of a USD 10.5 billion global strategic collaboration with Pfizer, as markets questioned regulatory approval certainty. Today's rebound was supported by broader biotech sector strength, with 3SBio rising 4.65% and Akeso gaining 1.14%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1104771647","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104771647","pubTimestamp":1781492694,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 15, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.7/share, with turnover of HKD 363 million. The stock rebounded after consecutive sessions of decline, driven by dual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规盘涨3.01%国产首个PCSK9抑制剂获批及ADA数据催化反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 15, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.7/share, with turnover of HKD 363 million. The stock rebounded after consecutive sessions of decline, driven by dual catalysts of a new product approval and academic conference data.The company recently received approval for its first domestic PCSK9 inhibitor injection, making it the tenth commercialized product in its portfolio and further strengthening its cardiovascular-metabolic pipeline. Additionally, mazdutide data presented at the 86th ADA Scientific Sessions — including three oral presentations covering severe obesity, type 2 diabetes with obesity, and adolescent obesity populations — provided further positive momentum.The stock had previously pulled back from its May 29 peak gain of over 11% following the announcement of a USD 10.5 billion global strategic collaboration with Pfizer, as markets questioned regulatory approval certainty. Today's rebound was supported by broader biotech sector strength, with 3SBio rising 4.65% and Akeso gaining 1.14%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104771647","isCrawlerRequest":true}